Therefore, emodin may become a new alternative or complementary drug for the treatment of T2DM, especially suitable for patients who are intolerant to metformin and acarbose or have severe adverse reactions, as well as those with low insulin sensitivity. This evidence concerns the gene INS and type 2 diabetes mellitus.